Source: https://patents.google.com/patent/US8114395
Timestamp: 2018-03-19 09:13:40
Document Index: 410934516

Matched Legal Cases: ['Application No. 2003248419', 'Application No. 2003248419', 'Application No. 2004279350', 'Application No. 2003248419', 'Application No. 2006257286', 'Application No. 200706014', 'Application No. 2', 'Application No. 2', 'Application No. 2', 'Application No. 2', 'Application No. 01104367', 'Application No. 01104367', 'Application No. 200680007733', 'Application No. 200480031909', 'Application No. 200480031909', 'Application No. 200480031910', 'Application No. 200680007733', 'Application No. 01104367', 'Application No. 200480031909', 'Application No. 200480031910', 'Application No. 200680007733', 'Application No. 01104367', 'Application No. 01104367', 'Application No. 01104367', 'Application No. 01104367', 'Application No. 02702211', 'Application No. 02702211', 'Application No. 02702211', 'Application No. 04809634', 'Application No. 04782529', 'Application No. 279', 'Application No. 310', 'Application No. 00310', 'Application No. 1214', 'Application No. 00311', 'Application No. 00311', 'Application No. 280', 'Application No. 2002', 'Application No. 2006', 'Application No. 2006', 'Application No. 2006', 'Application No. 2002', 'Application No. 200601204', 'Application No. 200601204', 'Application No. 200706014', 'Application No. 95107930', 'Application No. 095107930', 'Application No. 92', 'Application No. 92', 'Application No. 92']

US8114395B2 - Treatment of viral diseases with recombinant interferon α - Google Patents
Treatment of viral diseases with recombinant interferon α
US8114395B2
US8114395B2 US12105455 US10545508A US8114395B2 US 8114395 B2 US8114395 B2 US 8114395B2 US 12105455 US12105455 US 12105455 US 10545508 A US10545508 A US 10545508A US 8114395 B2 US8114395 B2 US 8114395B2
rsifn
US12105455
US20080305080A1 (en )
Rongbing Guo
Renhuai Zhang
Superlab Far East Ltd
Sichuan Biotechnology Research Center
10xPfu buffer (Stratagen American Ltd.) 5
N- Cys-Asp-Leu-Pro-Gln-Thr-His-Ser-Leu-Gly-Asn-
Arg-Arg-Ala-Leu
In pHY-5 plasmid, rSIFN-co gene is under control of strong promoter PBAD. This promoter is positively and negatively regulated by the product of the gene araC. AraC is a transcriptional regulator that forms a complex with arabinose. In the absence of arabinose, the AraC dimer binds O2 and I1 forming a 210 bp loop. This conformation leads to a complete inhibition of transcription. In the presence of arabinose, the dimer is released from O2 and binds I1 and I2 leading to transcription. Arabinose binding deactivates, represses and even activates the transcription of PBAD promoter, which stimulates PBAD inducing high expression of rSIFN-co rSIFN-co expression level in PVIII is more than 50% of the total E. Coli. protein.
+1 M C D L P Q T H S L G N R R A L I L L A
1 ATGTGCGACC TGCCGCAGAC CCACTCCCTG GGTAACCGTC GTGCTCTGAT CCTGCTGGCT
+1 Q M R R I S P F S C L K D R H D F G F P
61 CAGATGCGTC GTATCTCCCC GTTCTCCTGC CTGAAAGACC GTCACGACTT CGGTTTCCCG
+1 Q E E F D G N Q F Q K A Q A I S V L H E
121 CAGGAAGAAT TCGACGGTAA CCAGTTCCAG AAAGCTCAGG CTATCTCCGT TCTGCACGAA
+1 M I Q Q T F N L F S T K D S S A A W D E
181 ATGATCCAGC AGACCTTCAA CCTGTTCTCC ACCAAAGACT CCTCCGCTGC TTGGGACGAA
+1 S L L E K F Y T E L Y Q Q L N D L E A C
241 TCCCTGCTGG AAAAATTCTA CACCGAACTG TACCAGCAGC TGAACGACCT GGAAGCTTGC
+1 V I Q E V G V E E T P L M N V D S I L A
301 GTTATCCAGG AAGTTGGTGT TGAAGAAACC CCGCTGATGA ACGTTGACTC CATCCTGGCT
+1 V K K Y F Q R I T L Y L T E K K Y S P C
361 GTTAAAAAAT ACTTCCAGCG TATCACCCTG TACCTGACCG AAAAAAAATA CTCCCCGTGC
+1 A W E V V R A E I M R S F S L S T N L Q
421 GCTTGGGAAG TTGTTCGTGC TGAAATCATG CGTTCCTTCT CCCTGTCCAC CAACCTGCAG
+1 E R L R R K E # (SEQ ID NO: 2)
481 GAACGTCTGC GTCGTAAAGA ATAA (SEQ ID NO: 1)
Solution Lyophilized powder
Solution of rSIFN- 34.5 μg/ml 34.5 μg/ml
2. Dissolving dissolve rapidly in injection water(within
time 2 min) at room temperature
3. Clarity colorless liquid or with little milk-like
glisten; should not be cloudy, impurity or
with indiscernible deposit
5. Potency 80%~150% of indicated quantity (9 μg: 4.5 ×
(IU/dose) 106 IU, 15 μg: 7.5 × 106 IU)
3. Experiment Content
Example 4 rSIFN-co Inhibits HBV-DNA Duplication and Secretion of HBsAg and HBeAg
TC ⁢ ⁢ 50 = Antilog ⁡ ( B + 50 - B A - B × C )
1 ) ⁢ ⁢ Antigen ⁢ ⁢ inhibition ⁢ ⁢ rate ⁢ ⁢ ( % ) = A - B A × 100
Antigen ⁢ ⁢ inhibition ⁢ ⁢ IC ⁢ ⁢ 50 = Antilog ⁡ ( B + 50 - B A - B × C )
A log>50% medicine concentration, B=log<50% medicine concentration, C=log dilution power
SI = TC ⁢ ⁢ 50 IC ⁢ ⁢ 50
Inhibition rate Average Accumulated
Concentration First Second Third First Second Third inhibition 1- inhibition
PB (pH 7.0) 10 mmol/L
Influence to weights of mice after injection of
Non response: ALT, HBV-DNA and NBeAg unchanged
The response and partial response groups consider as effective cases.
Effective negative negative negative Recover
8-12 A rSIFN- 32 46.88 9.38 28.12 37.50 84.38
week co (9 μg) (15)  (3)  (9)  (12)  (27)
(5MU, 50 μg) (7)  (0)  (3)  (5)  (18)
16-24 A rSIFN- 64 54.69 7.81 25.00 34.38 90.62
week co (9 μg) (35)  (5)  (16)  (22)  (58)
(5MU, 50 μg) (16)  (0)  (6)  (12)  (50)
US12105455 2001-02-28 2008-04-18 Treatment of viral diseases with recombinant interferon α Active 2023-09-30 US8114395B2 (en)
CN 01104367 CN1245215C (en) 2001-02-28 2001-02-28 Recombination high efficiency composite interferon used as hepatitis B surface antigen and e antigen inhibitor
CN01104367.9 2001-02-28
PCT/CN2002/000128 WO2002080958A1 (en) 2001-02-28 2002-02-28 Recombination super compound interferon used as hepatitis b surface antigen and e antigen inhibitor
US10650365 US7364724B2 (en) 2001-02-28 2003-08-28 Recombinant super-compound interferon
US12105455 US8114395B2 (en) 2001-02-28 2008-04-18 Treatment of viral diseases with recombinant interferon α
US13019044 US8425896B2 (en) 2001-02-28 2011-02-01 Treatment of tumors with recombinant interferon alpha
US10650365 Continuation US7364724B2 (en) 2001-02-28 2003-08-28 Recombinant super-compound interferon
US13019044 Continuation US8425896B2 (en) 2001-02-28 2011-02-01 Treatment of tumors with recombinant interferon alpha
US20080305080A1 true US20080305080A1 (en) 2008-12-11
US8114395B2 true US8114395B2 (en) 2012-02-14
ID=4653854
US10650365 Active US7364724B2 (en) 2001-02-28 2003-08-28 Recombinant super-compound interferon
US12105455 Active 2023-09-30 US8114395B2 (en) 2001-02-28 2008-04-18 Treatment of viral diseases with recombinant interferon α
US13019044 Active US8425896B2 (en) 2001-02-28 2011-02-01 Treatment of tumors with recombinant interferon alpha
US (3) US7364724B2 (en)
JP (1) JP4617058B2 (en)
CN (1) CN1245215C (en)
CA (1) CA2439503A1 (en)
DE (1) DE60234085D1 (en)
EP (1) EP1371373B1 (en)
WO (1) WO2002080958A1 (en)
CN1740197B (en) 2004-08-26 2010-05-12 辉阳科技美国公司;四川省生物工程研究中心 Recombination interferon with new space conformation and enhanced effect, its preparing method and application
WO2013055811A1 (en) * 2011-10-12 2013-04-18 Hitachi Chemical Co., Ltd. Ex vivo methods of predicting responsiveness of a subject to interferon therapy
CA2897312A1 (en) * 2013-01-07 2014-07-10 Superlab Far East Limited Methods and compositions for treatment of bone, skin, subcutaneous, mucosal and/or submucosal cancer by percutaneous and/or transmucosal administration of interferon
EP0083734B1 (en) 1981-12-07 1986-03-05 F. HOFFMANN-LA ROCHE &amp; CO. Aktiengesellschaft Crystalline human leukocyte interferon
CN1099799A (en) 1993-05-26 1995-03-08 贝林格尔-英格海姆国际有限公司 Process for preparing and purifying alpha-interferon
DE4329756A1 (en) 1993-09-03 1995-03-09 Boehringer Ingelheim Int Process for the preparation and purification of alpha-interferon
WO1997027866A1 (en) 1996-02-05 1997-08-07 Amgen Inc. Methods for retreatment of patients afflicted with hepatitis c using consensus interferon
CN1186120A (en) 1996-12-24 1998-07-01 深圳科兴生物制品有限公司 Recombinative human interferon protein as secretory gene in colibacillus
WO1999040117A1 (en) 1998-02-06 1999-08-12 Ilexus Pty. Limited THREE-DIMENSIONAL STRUCTURES AND MODELS OF Fc RECEPTORS AND USES THEREOF
EP0736303B1 (en) 1995-04-06 1999-08-25 F. Hoffmann-La Roche Ag Interferon solution
CN1256148A (en) 1999-12-06 2000-06-14 天津华立达生物工程有限公司 Stable water solution of interferon
US6087478A (en) 1998-01-23 2000-07-11 The Rockefeller University Crystal of the N-terminal domain of a STAT protein and methods of use thereof
EP0777495B1 (en) 1994-10-11 2000-07-19 Schering Corporation Stable, aqueous alfa interferon solution formulations
US6114145A (en) 1997-12-05 2000-09-05 Human Genome Sciences, Inc. Synferon, a synthetic interferon
CN1062565C (en) 1998-06-29 2001-02-28 深圳九先生物工程有限公司 Recombinating haman alpha type composite interferon and preparation process and use thereof
WO2001035987A1 (en) 1999-11-19 2001-05-25 Lg Chem Investment, Ltd. An aqueous solution formulation of alpha-interferon
WO2002036627A2 (en) 2000-11-03 2002-05-10 Pbl Biomedical Laboratories Interferons, uses and compositions related thereto
WO2002080958A1 (en) 2001-02-28 2002-10-17 Sichuan Biotechnology Research Center Recombination super compound interferon used as hepatitis b surface antigen and e antigen inhibitor
CN1375502A (en) 2001-10-25 2002-10-23 南京药科大学 Polyglycol modified recombinant human interferon
CN1384116A (en) 2002-05-16 2002-12-11 中国人民解放军第二军医大学 New-type alpha-interferon
US6546074B1 (en) 2001-03-27 2003-04-08 Astex Technology Limited Protein crystal structure and method for identifying protein modulators
CN1478545A (en) 2003-07-18 2004-03-03 中国科学院微生物研究所 Use of compound interferon in the treating of SARS disease
US20040115169A1 (en) 2000-10-27 2004-06-17 Chiron Corporation Methods of protein purification and recovery
WO2005021777A2 (en) 2003-08-28 2005-03-10 Huiyangtech (Usa), Inc. Uses of spatial configuration to modulate protein function
WO2006134497A2 (en) 2005-03-09 2006-12-21 Guangwen Wei Uses of recombinant super-compound interferons
CN1098103C (en) 1992-04-15 2003-01-08 安姆根有限公司 Pharmaceutical use of sympathetic human white-cell interferon
CN1120846A (en) 1993-02-25 1996-04-17 先灵公司 Metal-interferon-alpha crystals
US5602232A (en) 1993-02-25 1997-02-11 Schering Corporation Method for producing metal-interferon-α crystals
US5710027A (en) 1993-05-26 1998-01-20 Boehringer Ingelheim International Gmbh Process and vector for expressing alpha-interferon in E. coli
US6579695B1 (en) 1995-10-13 2003-06-17 President And Fellows Of Harvard College Phosphopantetheinyl transferases and uses thereof
CN1217660A (en) 1996-02-05 1999-05-26 安姆根有限公司 Method for retreatment of patients afflicted with Hepatitis C using consensus interferon
CN1291198A (en) 1998-02-06 2001-04-11 伊来克萨斯独资有限公司 Three-dimesional structures and models of Fc receptors and use thereof
US20040202641A1 (en) 2001-02-28 2004-10-14 Sichuan Biotechnology Research Center Recombinant super-compound interferon
WO2005034853A2 (en) 2003-08-28 2005-04-21 Huiyangtech (Usa), Inc. Uses of interferons with altered spatial structure
Advisory Action Before the Filing of an Appeal Brief for Guangwen Wei, U.S. Appl. No. 10/928,474, filed Aug. 26, 2004, Dated May 22, 2007.
Advisory Action Before the Filing of an Appeal Brief, Jul. 17, 2008, for Guangwen Wei, U.S. Appl. No. 11/077,813, filed Mar. 10, 2005.
Advisory Action before the Filing of an Appeal Brief, U.S. Appl. No. 10/928,474, filed Aug. 28, 2003, Dated Mar. 18, 2008.
Alton, K. et al., 1983, "Production, characterization and biological effects of recombinant DNA derived human IFN-α and IFN-γ analogs." In: De Maeger E, Schellekens H. eds. The Biology of Interferon System 2nd ed. Amsterdam: Elsevier Science Publishers, p. 119-128.
Amato, Ivan, Jan. 22, 2007, "Silent No Longer: Researchers Unearth another Stratum of Meaning in the Genetic Code," Chemical and Engineering News, 85(4):38-40.
Apeler, H. et al., Aug. 1, 1997, "Expression of Natural and Synthetic Genes Encoding Herpes Simplex Virus 1 Protease in Escherichia coli and Purification of the Protein," European Journal of Biochemistry, 247 (3):890-895, XP002318941, ISSN: 0014-2956.
Australian Examiner's Report for Sichuan Biotechnology Research Center, Australian Application No. 2003248419, Filed Sep. 26, 2003, Dated Dec. 12, 2005.
Australian Examiner's Report for Sichuan Biotechnology Research Center, Australian Application No. 2003248419, Filed Sep. 26, 2003, Dated Jun. 1, 2006.
Australian Examiner's Report for Sichuan Biotechnology Research Center, Australian Application No. 2004279350 Dated Mar. 1, 2010.
Australian Notice of Acceptance for Sichuan Biotechnology Research Center, Australian Application No. 2003248419, Filed Sep. 26, 2003, Dated Dec. 18, 2006.
Australian Office Action, Mar. 28, 2011, Guangwen Wei, Australian Application No. 2006257286, Filed Aug. 8, 2007.
Austrian Written Opinion, Jun. 29, 2009, Singapore Application No. 200706014-8, Guangwen Wei, filed Mar. 9, 2006.
Ausubel et al., Eds., 1999, Chapter Ten, "Analysis of Proteins," from Short Protocols in Molecular Biology, 4th ed., p. 10-1 to 10-8.
Bingfa et al., 2009, "Anti-Hepatitis B Virus Activity and Mechanisms of Recombinant Human Serum Albumin-Interferon-α-2b Fusion Protein in vitro and in vivo", Pharmacology, 83:323-332.
Blatt, L.M. et al., 1996, "The biological activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon," Journal of Interferon and Cytokine Research, 16(7):489-499.
Canadian Offica Action, May 10, 2011, Huiyangtech (USA), Inc, Canadian Application No. 2,535,982, Filed Feb. 15, 2006, corresponding to Int'l App'l No. PCT/US2004/028067, Filed Aug. 26, 2004.
Canadian Office Action, Apr. 21, 2008, for Sichuan Biotechnolgy Research Center, Canadian Application No. 2,439,503, Filed Aug. 27, 2003.
Canadian Office Action, Jun. 1, 2009, Sichuan Biotechnolgy Research Center, Canadian Application No. 2,439,503, Filed Aug. 27, 2003.
Canadian Office Action, Mar. 8, 2011, Sichuan Biotechnology Research Center, Canadian Application No. 2,439,503, Filed Aug. 27, 2003.
Cao, Hongpeng, and Tao, Peizhen, "Effect of Anti-HBV of 6 Drugs Include Lamividine," Natl. Med. J. China, 2001, 81(16):1004-1007.
Chinese Decision About Rejection, Nov. 12, 2004, for Sichuan Biological Research Center, Chinese Application No. 01104367.9, Filed Feb. 28, 2001. [with full English translation].
Chinese Decision About the Reexamination, Oct. 26, 2005, for Sichuan Biological Research Center, Chinese Application No. 01104367.9, Filed Feb. 28, 2001. [with full English translation].
Chinese Examination Report, Aug. 25, 2010, Huiyangtech(USA), Inc., Chinese Application No. 200680007733.1 ((With English summary), Filed Sep. 10, 2007.
Chinese Examination Report, Aug. 7, 2009, Huiyangtech(USA), Inc., Chinese Application No. 200480031909.8, Filed Apr. 28, 2006.
Chinese Examination Report, Feb. 20, 2009, Huiyangtech(USA), Inc., Chinese Application No. 200480031909.8, Filed Apr. 28, 2006.
Chinese Examination Report, Nov. 20, 2009, Huiyangtech(USA), Inc., Chinese Patent Application No. 200480031910.0, Filed Apr. 28, 2006.
Chinese Examination Report, Nov. 27, 2009, Huiyangtech(USA), Inc., Chinese Application No. 200680007733.1, Filed Sep. 10, 2007.
Chinese First Notification of Examination, Apr. 18, 2003, for Sichuan Biological Research Center, Chinese Application No. 01104367.9, Filed Feb. 28, 2001. [with full English translation].
Chinese First Office Action, Feb. 20, 2009, for Huiyangtech (USA), Inc., Chinese Application No. 200480031909.8, Filed Apr. 28, 2006.
Chinese First Office Action, Mar. 27, 2009, for Huiyangtech (USA), Inc., Chinese Application No. 200480031910.0, Filed Apr. 28, 2006.
Chinese First Office Action, May 22, 2009, for Guangwen Wei, Chinese Application No. 200680007733.1, Filed Sep. 10, 2007.
Chinese Fourth Notification of Examination, Jun. 4, 2004, for Sichuan Biological Research Center, Chinese Application No. 01104367.9, Filed Feb. 28, 2001. [with full English translation].
Chinese Notification of Patent for Invention, Oct. 26, 2005, for Sichuan Biological Research Center, Chinese Application No. 01104367.9, Filed Feb. 28, 2001. [with full English translation].
Chinese Second Notification of Examination, Oct. 17, 2003, for Sichuan Biological Research Center, Chinese Application No. 01104367.9, Filed Feb. 28, 2001. [with full English translation].
Chinese Third Notification of Examination, Jan. 2, 2004, for Sichuan Biological Research Center, Chinese Application No. 01104367.9, Filed Feb. 28, 2001. [with full English translation].
Cinatl et al., 2003, "Treatment of SARS with Human Interferons," The Lancet, 362:293-294.
Day et al., 1992, "Engineered Disulfide Bond Greatly Increases Specific Activity of Recombinant Murine Interferon-Beta," Journal of Interferon Res., 12:139-143.
Duan et al., 2003, "Anti-SARS virus activities of different recombinant human interferons in cell culture system," Chinese J. Clin. Virol., 17(3):205-208.
European Communication for Sichuan Biotechnology Research Center, European Application No. 02702211.0, Filed Sep. 25, 2003, Dated Dec. 14, 2006.
European Communication, Aug. 26, 2008, for Sichuan Biological Research Center, European Application No. 02702211.0, Filed Mar. 23, 2006.
European Communication, Jun. 19, 2006, for Sichuan Biological Research Center, European Application No. 02702211.0, Filed Mar. 23, 2006.
European Communication, Jun. 19, 2009, Sichuan Biotechnology Research Center, European App'l No. 02702211.0, Filed Sep. 25, 2003.
European Communication, Nov. 27, 2008, for Huiyangtech (USA), Inc., European Application No. EP 04782529.4, Filed Mar. 23, 2006.
European Communication, Nov. 28, 2008, for Huiyangtech (USA), Inc., European Application No. EP 04809634.1, Filed Mar. 23, 2006.
European Examiner's Report, Jan. 14, 2011, Sichuan Biotechnology Research Center, European Patent Application No. EP 04809634.1, Filed Mar. 23, 2006.
European Examiner's Report, Jul. 28, 2009, Huiyangtech(USA), Inc., European Application No. 04809634.1, Filed Mar. 26, 2006.
European Examiner's Report, Jul. 29, 2009, Huiyangtech(USA), Inc., European Application No. 04782529.4, Filed Mar. 23, 2006.
European Search Report for Huiyangtech (USA), Inc., Apr. 26, 2011, Application No. EP 10 19 3126.
Examiner's Report for Wei et al., European App'l No. 02702211.0, Filed Sep. 25, 2003, Dated Dec. 13, 2007.
Examiner's Written Opinion for Huiyangtech (USA), Inc., Singaporean App'l No. 200601209-0, Filed Feb. 23, 2006, Dated Jan. 8, 2008.
Fei et al., 1999, "Clinical Observation of Effect on Treatment of Chronic Hepatitis B by a Combination of Interferon and Lamividine," Shandong Medical Journal, 39(11):3-4.
Gao et al., 1999, "Treatment of Hepatitis Virus Related Pediatric Nephritis With IFN," Academic Journal Of Jinlin Hospital, 12(1):155-157.
Gao Zhan-Cheng et al., 2003, "Clinical investigation of outbreak of nosocomial severe acute respiratory syndrome", Database Medline, Database accession No. NLM12837162.
Greenberg et al., Sep. 2, 1976, "Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis", 295(10):517-522. (abstract only).
Guzman, Luz-Maria et al, 1995, "Tight Regulation, Modulation, and High-Level Expression by Vectors Containing the Arabinose P-Bad Promoter," Journal of Bacteriology, 177(14):4121-4130, Xp002121022, ISSN: 0021-9193.
Heathcote, E.J.L. et al., 1998, "Re-treatment of chronic hepatitis C with consensus interferon," Hepatology 27(4):1136-1143.
Higgins et al., 1983, "Intranasal Interferon as Protection against Experimental Respiratory Coronavirus Infection in Volunteers," Antimicrobial Agents and Chemotherapy 24(5):713-715.
Holland, C.C. and T.L. Wright, "New approaches to treatment of chronic viral hepatitis," Pathology (Phila.), 1994: 3(1), Full Article.
Huang, Wanzhi et al., Jun. 72, 2000, "Use of the Arabinose pBAD Promoter for Tightly Regulated Display of Proteins on Bacteriophage," Gene (Amsterdam), 251(2):187-197, XP004206676, ISSN: 0378-1119.
Indian Examination Report for Sichuan Biotechnology Research Center, Indian Application No. 279/MUM/2004, Filed Mar. 5, 2004, Dated Aug. 2, 2007.
Indian Examination Report, Aug. 1, 2008, for Huiyangtech(USA), Inc., Indian Application No. 310/MUMUMP/2006, Filed Oct. 3, 2006.
Indian Examiner's Report, Aug. 20, 2009, Indian Application No. 00310/MUMNP/2006, Wei et al., Filed Oct. 17, 2007.
Indian Examiner's Report, May 10, 2010, Indian Application No. 1214/MUMNP/2007, Guangwen Wei, Filed Aug. 13, 2007.
Indian Examiner's Report, May 4, 2010, Indian Application No. 00311/MUMNP/2006, Huiyangtech (USA) Inc., Filed Mar. 24, 2006.
Indian Examiner's Report, Sep. 16, 2009, Indian Application No. 00311/MUMNP/2006, Huiyangtech (USA) Inc., Filed Mar. 24, 2006.
Indian Office Action, Oct. 24, 2008, for Sichuan Biological Research Center, Indian Patent Application No. 280/MUM/2004, Filed Mar. 5, 2004.
Indian patent for 279/MUM/2004, Jan. 28, 2009, Sichuan Biological Research Center.
Infergen (Interferon alfacon-1) Product Sheet, Amgen, Inc., Issue Date: Nov. 30, 1998.
International Preliminary Examination Report, Application No. PCT/CN02/00128 for Sichuan Biotechnology Research Center, "Recombination Super Compound Interferon Used as Hepatitis B Surface Antigen and E Antigen Inhibitor," Filed Feb. 28, 2002, Dated Feb. 15, 2004.
International Search Report, Application No. PCT/CN02/00128 for Sichuan Biotechnology Research Center, "Recombination Super Compound Interferon Used as Hepatitis B Surface Antigen and E Antigen Inhibitor," Filed Feb. 28, 2002, Dated Aug. 8, 2002, Date of Completion of the Search: Jul. 23, 2002.
International Search Report, Application No. PCT/US04/28068 for Huiyangtech (USA) Inc., Filed Aug. 26, 2004, Dated Mar. 4, 2005.
International Search Report, Application No. PCT/US2004/028067 for Huiyangtech, Inc., "Uses of interferons with altered spatial structure," Filed Aug. 26, 2004, Dated Feb. 27, 2006, Date of Completion of the Search: Nov. 2, 2005.
Japanese Examiner's Report, Dec. 2, 2009, Sichuan Biotechnology Research Center, Japanese Patent Application No. 2002-578997, Filed Aug. 28, 2003.
Japanese Examiner's Report, Dec. 28, 2010, Sichuan Biotechnology Research Center, Japanese Patent Application No. 2006-524916, Filed Feb. 27, 2006.
Japanese Examiner's Report, Jul. 26, 2010, Huiyangtech (USA), Inc., Japanese Patent Application No. 2006-524916, Filed Feb. 27, 2006 (with English summary).
Japanese Examiner's Report, May 10, 2010, Huiyangtech (USA), Inc., Japanese Patent Application No. 2006-524916, Filed Feb. 27, 2006.
Japanese Notification of Reasons of Refusal, Jun. 17, 2008, for Sichuan Biotechnology Research Center, Japanese Application No. 2002-578997, Filed Aug. 28, 2003. [with full English translation].
Klein, M.L. et al., 1998, "Structural character-ization of recombinant consensus interferon-alpha," Journal of Chromatography, 454:205-215.
Krogsgaard et al., 1996, "Relation Between efficacy and cumulative dose of alpha interferon in chronic hepatitis B. European Concerted Action on Viral Hepatitis (Eurohep)", J Hepatology, 25(6):795-802.
Lang et al., 2002, "Observation on Serology And Histology Of Patients With Chronic Hepatitis B After Interferon Treatment," Chin. J. Infect. Dis., 20(2): 97-100.
Lei et al., 1995, "Observation on Clinical Treatment of Chronic Hepatitis B by Purified Human Leucocyte Interferon," Chinese Journal Of Practical Internal Medicine, 15(3)155-157.
Li et al., 1999, "Antiviral effects of rhIFN-alpha 1 against seven influenza viruses", Acta. Pharmacol. Sin. 20(8):709-714.
Loufty et al., 2003, "Interferon Alfacon-1 Plus Corticosteroids in Severe Acute Respiratory Syndrome—A preliminary Study", JAMA, 290(24):3222-3228.
Malaysian Advisory Action, Mar. 8, 2007, Sichuan Biotechnology Research Center, Malaysian Patent Application No. PI 20033246, Filed Aug. 28, 2003.
Malaysian Examiner's Report for Sichuan Biotechnology Research Center, Malaysian Application No. PI 20033246, Filed Aug. 28, 2003, Dated Mar. 8, 2007.
Malaysian Office Action, Aug. 11, 2008, for Sichuan Biological Research Center, Malaysian Patent Application No. PI 20033246, Filed Aug. 28, 2003.
Malaysian Office Action, Jan. 16, 2009, for Sichuan Biological Research Center, Malaysian Patent Application No. PI 20033246, Filed Aug. 28, 2003.
Malaysian Office Action, Jul. 13, 2009, Guangwen Wei, Malaysian Patent Application No. PI 20061015, Filed Mar. 9, 2006.
Moore et al., 1995, "A Phase I Study of Intraperitoneal Interferon-α2b cis-Platinum plus Cyclophosphamide Chemotherapy in Patients with Untreated Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Pilot Study", Gynecologic Oncology, 59:267-272.
Nackley, A.G. et al., Dec. 22, 2006, "Human Catechol-O-Methyltransferase Haplotypes Modulate Protein Expression by Altering mRNA Secondary Structure," Science, 314:1930-1932.
Nasoff et al., 1999, "High-Level Expression of Human Genes in E. coli," Expression, 6(2):10-11.
Notice of Allowance and Fee(s) Due notice for Wei et al., U.S. Appl. No. 10/650,365, filed Aug. 28, 2003, dated Jul. 26, 2007.
Notice of Allowance for Wei et al., U.S. Appl. No. 10/650,365, filed Aug. 28, 2003, Dated Dec. 12, 2007.
Notice of Allowance for Wei et al., U.S. Appl. No. 10/928,956, filed Aug. 26, 2004, Dated Apr. 2, 2008.
Notification Concerning Transmittal of International Preliminary Report on Patentability (Chapter I of the Patent Cooperation Treaty) for PCT/IB2006/002340 for Guangwen Wei, Dated Sep. 20, 2007.
Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority for Guangwen Wei (International Search Report and Written Opinion included), Application No. PCT/IB2006/002340, Filed Mar. 9, 2006, Dated May 10, 2007.
Ozes, O.N. et al., 1992, "A comparison of interferon-con1 with natural recombinant interferons: antiviral, antiproliferative, and natural killer-inducing activities." J. Interferon Res., 12:55-59.
pBAD Expression System, "Tightly Controlled Bacterial Protein Expression," Invitrogen Corp. Publication, 2002.
PCT Notification of Transmittal of International Preliminary Report on Patentability for Huiyangtech (USA) Inc., International Application No. PCT/US04/28068, Filed Aug. 26, 2004, Dated May 13, 2005.
Pfeffer, L.M., 1997, "Biologic activity of natural and synthetic type 1 interferons," Seminars in Oncology, 24(3 suppl. 9):S9-63-S9-69.
Pyrc, K. et al., 2007, "Antiviral strategies against human coronaviruses," Infectious Disorders-Drug Targets, (7):59-66.
Pyrc, K. et al., 2007, "Antiviral strategies against human coronaviruses," Infectious Disorders—Drug Targets, (7):59-66.
Schulte-Frohlinde, et al., Feb. 21, 2002, "Different Activities of Type I interferons on Hepatitis B virus core promoter regulated transcription." Cytokine, 17(4): 214-220. [Cited by Examiner in Advisory Action of Mar. 18, 2008].
Singapore grant for 200304969, Nov. 30, 2005, Sichuan Biological Research Center.
Singapore grant for 200601204-1, Mar. 31, 2009, Huitangtech(USA), Inc.
Singapore Written Opinion for Huiyangtech (USA), Inc., Singapore Application No. 200601204-1, Filed Feb. 23, 2006, Dated Jul. 19, 2007.
Singapore Written Opinion, Apr. 29, 2008, for Huiyangtech (USA), Inc., Singapore Application No. 200601204-1, Filed Feb. 23, 2006.
Singapore Written Opinion, Mar. 26, 2010, Guangwen Wei, Singapore Application No. 200706014-8, Filed Aug. 15, 2007.
Spada S., 2004, "Infergen", Directory of Approved Biopharmaceutic. Prod., 116-117.
Supplementary European Search Report for Sichuan Biotechnology Research Center, Application No. EP 02702211, Filed Feb. 28, 2002, Date Of Completing Of The Search: Feb. 23, 2005.
Taiwanese Examination Report, Dec. 12, 2008, for Guangwen Wei, Taiwanese Application No. 95107930, Filed Mar. 9, 2006. [with full English translation].
Taiwanese Examiner's Report, Mar. 2010, Huiyangtech(USA), Inc., Taiwanese App'l No. 92,123,846, Filed Aug. 28, 2003.
Taiwanese Examiner's Report, May 25, 2009, Huiyangtech(USA), Inc., Taiwanese Application No. 095107930, Filed Mar. 9, 2006.
Taiwanese Formal Rejection for Sichuan Biotechnology Research Center, Taiwanese Application No. 92,123,846, Filed Aug. 28, 2003, Dated Dec. 29, 2006.
Taiwanese Formal Rejection, Dec. 11, 2006, for Sichuan Biotechnology Research Center, Taiwanese Application No. 92,123,846, Filed Aug. 28, 2003. [with full English translation].
Taiwanese Office Action for Sichuan Biotechnology Research Center, Taiwanese Application No. 92,123,846, Filed Aug. 28, 2003, Dated Sep. 21, 2006.
U.S Office Action, Jun. 20, 2011, Guangwen Wei, U.S. Appl. No. 12/246,153, Filed Oct. 6, 2008.
U.S. Examiner's Answer to Appeal Brief, Dec. 9, 2008, for Guangwen Wei, U.S. Appl. No. 10/928,474, filed Aug. 26, 2004.
U.S. Final Office Action, Apr. 15, 2009, for Guangwen Wei, U.S. Appl. No. 10/927,975, filed Aug. 26, 2004.
U.S. Notice of Allowance and Fee(s) Due, Jun. 25, 2008, for Guangwen Wei, U.S. Appl. No. 10/928,956, filed Aug. 26, 2004.
U.S. Notice of Allowance and Fee(s) Due, Sep. 22, 2008, for Guangwen Wei, U.S. Appl. No. 10/928,956, filed Aug. 26, 2004.
U.S. Office Action for Guangwen Wei, U.S. Appl. No. 10/927,975, filed Aug. 26, 2004, Dated Apr. 2, 2008.
U.S. Office Action for Guangwen Wei, U.S. Appl. No. 10/927,975, filed Aug. 26, 2004, Dated Apr. 3, 2007.
U.S. Office Action for Guangwen Wei, U.S. Appl. No. 10/927,975, filed Aug. 26, 2004, Dated Sep. 19, 2007.
U.S. Office Action for Guangwen Wei, U.S. Appl. No. 10/928,474, filed Aug. 26, 2004, Dated Aug. 22, 2006.
U.S. Office Action for Guangwen Wei, U.S. Appl. No. 10/928,474, filed Aug. 26, 2004, Dated Aug. 9, 2007.
U.S. Office Action for Guangwen Wei, U.S. Appl. No. 10/928,474, filed Aug. 26, 2004, Dated Feb. 9, 2007.
U.S. Office Action for Guangwen Wei, U.S. Appl. No. 10/928,474, filed Aug. 26, 2004, Dated Jan. 4, 2008.
U.S. Office Action for Guangwen Wei, U.S. Appl. No. 10/928,956, filed Aug. 26, 2004, Dated Dec. 15, 2006.
U.S. Office Action for Guangwen Wei, U.S. Appl. No. 10/928,956, filed Aug. 26, 2004, Dated Jun. 14, 2007.
U.S. Office Action for Guangwen Wei, U.S. Appl. No. 11/077,813, filed Mar. 10, 2005, Dated Aug. 1, 2007.
U.S. Office Action for Guangwen Wei, U.S. Appl. No. 11/077,813, filed Mar. 10, 2005, Dated Aug. 8, 2006.
U.S. Office Action for Guangwen Wei, U.S. Appl. No. 11/077,813, filed Mar. 10, 2005, Dated Feb. 6, 2008.
U.S. Office Action for Guangwen Wei, U.S. Appl. No. 11/077,813, filed Mar. 10, 2005, Dated Nov. 27, 2006.
U.S. Office Action for Wei et al., U.S. Appl. No. 10/650,365, filed Aug. 28, 2003, Dated Aug. 23, 2005.
U.S. Office Action for Wei et al., U.S. Appl. No. 10/650,365, filed Aug. 28, 2003, Dated Mar. 20, 2006.
U.S. Office Action for Wei et al., U.S. Appl. No. 10/650,365, filed Aug. 28, 2003, Dated Mar. 7, 2007.
U.S. Office Action for Wei et al., U.S. Appl. No. 10/650,365, filed Aug. 28, 2003, Dated Sep. 20, 2006.
U.S. Office Action, Apr. 15, 2010, for Guangwen Wei, U.S. Appl. No. 12/369,005, filed Feb. 11, 2009.
U.S. Office Action, Apr. 29, 2005, for Guangwen Wei, U.S. Appl. No. 10/650,365, Patent No. 7,364,724, filed Aug. 28, 2003.
U.S. Office Action, Aug. 2, 2010, Guangwen Wei, U.S. Appl. No. 12/369,005, Filed Feb. 11, 2009.
U.S. Office Action, Aug. 4, 2010, Guangwen Wei, U.S. Appl. No. 12/246,153, Filed Oct. 6, 2008.
U.S. Office Action, Aug. 8, 2006, for Guangwen Wei, U.S. Appl. No. 10/928,956, filed Aug. 26, 2004.
U.S. Office Action, Dec, 17, 2010, for Guangwen Wei, U.S. Appl. No. 12/246,153, Filed Oct. 6, 2008.
U.S. Office Action, Dec. 2, 2009 Guangwen Wei, U.S. Appl. No. 10/927,975, filed Aug. 26, 2004.
U.S. Office Action, Dec. 22, 2010, for Guangwen Wei, U.S. Appl. No. 12/554,297, Filed Sep. 4, 2009.
U.S. Office Action, Feb. 23, 2009, for Guangwen Wei, U.S. Appl. No. 11/817,926, filed Sep. 6, 2007.
U.S. Office Action, Jan. 25, 2011, Guangwen Wei, U.S. Appl. No. 10/928,474, Filed Aug. 26, 2004.
U.S. Office Action, Jan. 6, 2010, Guangwen Wei, U.S. Appl. No. 12/246,153, filed Oct. 6, 2008.
U.S. Office Action, Jun. 14,2011, Guangwen Wei, U.S. Appl. No. 12/554,297, Filed Sep. 4, 2009.
U.S. Office Action, Jun. 23, 2009, Guangwen Wei, U.S. Appl. No. 10/927,975, filed Aug. 26, 2004.
U.S. Office Action, Nov. 14, 2008, for Guangwen Wei, U.S. Appl. No. 10/927,975, filed Aug. 26, 2004.
U.S. Office Action, Sep. 29, 2009, Guangwen Wei, U.S. Appl. No. 11/817,926, filed Mar. 9, 2005.
U.S. Office Action, Sep. 30, 2009, Guangwen Wei, U.S. Appl. No. 12/369,005, filed Feb. 11, 2009.
Wang, C. et al., 2006, "Refolding Recombinant Human Granulocyte Colony Stimulating Factor Expressed by E. coli: A Case Study Using the Unit of Simultaneous Renaturation and Purification of Proteins," BioProcess International, 48-53.
Wang, Xiangye, and Li, Xuegang, 1994, "Comparing Effect of Three Drugs on Turning HBEAG to Negative," Qienwei Medical Journal, 11(4):197-198.
Wong, Samson S. Y. and Yuen, Kwok-Yung, 2008, "The management of coronavirus infections with particular reference to SARS", Journal of Antimicrobial Chemotherapy, 62:437-441.
Written Opinion for Huiyangtech (USA) Inc., International Searching Authority for PCT/US04/28068, Filed Aug. 26, 2004, Dated Mar. 4, 2005.
Written Opinion of the Australian Patent Office for SG 200601209-0, National Phase under Chapter II Based on PCT/US2004/028067 for Huiyangtech (USA) Inc., Dated Dec. 4, 2007.
Written Opinion of the International Searching Authority for PCT/US2004/028067, Dated Aug. 26, 2004 for Huiyangtech (USA) Inc., Dated Nov. 2, 2005.
Wu, et al., 2003, "A hospital outbreak of severe acute respiratory syndrome in Guangzhou, China." Chinese Medicine Journal, 116(6):811-818.
Yasuda, et al., 2000, "Spectrum of virus inhibition by consensus interferon YM643." Antiviral Chemistry & Chemotherapy, 11:337-341.
Zeng, Zheng et al., 2000, "Transfer and expression of human interferon-α and its effect on HBV inhibition," Chinese Journal of Infectious Disease, 18(4):221-224. [English abstract only].
Zhao, Z. et al., 2003, "Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China," Journal of Med. Microbiol. 52:715-720.
Zheng, B. et al., 2004, "Potent inhibition of SARS-associated coronavirus (SCOV) infection and replication by type I interferons (IFN-alpha/beta) but not by type II interferon (IFN-gamma)," J. Interferon Cytokine Res., 24(7):288-90. [Abstract only].
US20080305080A1 (en) 2008-12-11 application
CA2439503A1 (en) 2002-10-17 application
CN1245215C (en) 2006-03-15 grant
EP1371373A1 (en) 2003-12-17 application
DE60234085D1 (en) 2009-12-03 grant
CN1311035A (en) 2001-09-05 application
US20040202641A1 (en) 2004-10-14 application
JP4617058B2 (en) 2011-01-19 grant
EP1371373B1 (en) 2009-10-21 grant
JP2005508848A (en) 2005-04-07 application
US20110189128A1 (en) 2011-08-04 application
US8425896B2 (en) 2013-04-23 grant
WO2002080958A1 (en) 2002-10-17 application
EP1371373A4 (en) 2005-05-04 application
US7364724B2 (en) 2008-04-29 grant
Weck et al. 1981 Antiviral activities of hybrids of two major human leukocyte interferons
US5595888A (en) 1997-01-21 Recombinant methods of making gamma interferon compositions
Pestka et al. 1981 [1] Definition and classification of the interferons
US4914033A (en) 1990-04-03 Structure and properties of modified interferons
Borden et al. 1984 Antiproliferative activities of interferons against human bladder carcinoma cell lines in vitro
WO1986004587A1 (en) 1986-08-14 Purification of native colony stimulating factor-1
US4753795A (en) 1988-06-28 Modified (80-113) beta interferons
WO1983002461A1 (en) 1983-07-21 Multiclass hybrid interferons
Pestka 1983 The purification and manufacture of human interferons
EP0845530A2 (en) 1998-06-03 Interferon gamma inducing factor
Owner name: SICHUAN BIOTECHNOLOGY RESEARCH CENTER, CHINA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WEI, GUANGWEN;GUO, RONGBING;ZHANG, RENHUAI;REEL/FRAME:021475/0115
Owner name: SUPERLAB FAR EAST LIMITED, VIRGIN ISLANDS, BRITISH
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SICHUAN BIOTECHNOLOGY RESEARCH CENTER;REEL/FRAME:037107/0576